Medicare will require data on patient use for approved Alzheimer’s drugs
By Julie Steenhuysen (Reuters) -The U.S. Medicare health plan said on Thursday it would limit reimbursement for Eisai Co Ltd and Biogen Inc’s Alzheimer’s drug Leqembi to patients whose doctors participate in a health agency database should the drug win full approval, a move advocates say will hinder its use. Leqembi received accelerated approval from the FDA in January, based on limited evidence suggesting it would slow cognitive decline in […]